Overcoming psychological barriers in insulin therapy

Insulin

Volumn 1, Issue 1, 2006, Pages 38-45

  Logan Stotland, Nada ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

fear of hypoglycemia; injection anxiety; insulin therapy; needle phobia; psychological barriers in people with diabetes; weight gain

Indexed keywords

GLUCOSE; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN;

ANXIETY; ARTICLE; AWARENESS; DECISION MAKING; DEPRESSION; DIABETES CONTROL; DIABETES MELLITUS; DOCTOR PATIENT RELATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION; INSULIN TREATMENT; INTERPERSONAL COMMUNICATION; MEDLINE; NEEDLE; OBESITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PHOBIA; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; WEIGHT GAIN;

EID: 33745649251     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(06)80006-0     Document Type: Article

References (41)

1. The Diabetes Control and Complications Trial Research Group^. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
2. Ohkubo Y., Kishikawa H., Arald E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: A randomized, prospective 6-year study. Diabetes Res Clin Pract 28 (1995) 103-117
3. [published correction appears in Lancet. 1999; 354:602]. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
4. Klein R., Klein B.E., Moss S.E., and Cruickshanks K.J. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 154 (1994) 2169-2178
5. Turner R.C., Cull C.A., Fright V., Holman R.R., and UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
6. Mollema E.D., Snoek F.L., Ader H.J., et al. Insulin-treated diabetes patients with fear of self injecting or fear of selftesting: Psychological comorbidity and general wellbeing. J Psychosom Res 51 (2001) 665-672
7. Bryden K.S., Neil A., Mayon R.A., et al. Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care 22 (1999) 1956-1960
8. Zambanini A., Newson R.B., Maisey M., and Feher M.D. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 46 (1999) 239-246
9. Pibernik-Okanovic M., Prasek M., Poljicanin-Filipovic T., et al. Effects of an empowerment-based psychosocial intervention on quality of life and metabolic control in type 2 diabetic patients. Patient Educ Couns 52 (2004) 193-199
10. Banister N.A., Jastrow S.T., Hodges V., et al. Diabetes selfmanagement training program in a community clinic improves patient outcomes at modest cost. J Am Diet Assoc 104 (2004) 807-810
11. Mollema E.D., Snoek F.L., Heine R.J., and van der Ploeg H.M. Phobia of self-injecting and self testing in insulin-treated diabetes patients: Opportunities for screening. Diabet Med 18 (2001) 671-674
12. Berlin I., Bisserbe J.C., Eiber R., et al. Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. Diabetes Care 20 (1997) 176-178
13. Lustman P.L., Griffith L.S., Clouse R.E., and Cryer P.E. Psychiatric illness in diabetes mellitus. Relationship to symptoms and glucose control. J Nerv Ment Dis 174 (1986) 736-742
14. Brown L.C., Majumdar S.R., Newman S.C., and Johnson J.A. History of depression increases risk of type 2 diabetes in younger adults. Diabetes Care 28 (2005) 1063-1067
15. Hunt L.M., Valenzuela M.A., and Pugh J.A. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 20 (1997) 292-298
16. Korytkowski M., Bell D., Jacobsen C., Suwannasari R., and FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 25 (2003) 2836-2848
17. Skyler I.S., Weinstock R.S., Raskin P., et al., Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care 28 (2005) 1630-1635
18. Polonsky W.H., Anderson B.L., Lohrer P.A., et al. Insulin omission in women with IDDM. Diabetes Care 17 (1994) 1178-1185
19. Albu J., and Raja-Khan N. The management of the obese diabetic patient. Prim Care 30 (2003) 465-491
20. [published correction appears in JAMA. 1998;280:1484]. Purnell J.O., Hokanson J.E., Marcovina S.M., et al., Diabetes Control and Complications Trial. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT. JAMA 280 (1998) 140-146
21. Larger E., Rufat P., Dubois-Laforgue D., and Ledoux S. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes. Diabetes Care 24 (2001) 1849-1850
22. Harris M.I., Klein R., Welborn T.A., and Knuiman M.W. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15 (1992) 815-819
23. Kudlacek S., and Schernthaner G. The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas: five year follow-up study. Horm Metab Res 24 (1992) 478-483
24. Heinemann L., Linkeschova R., Rave K., et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23 (2000) 644-649
25. Rosenstock J., Schwartz S.L., Clark Jr. C.M., et al. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE901) and NPH insulin. Diabetes Care 24 (2001) 631-636
26. De Leeuw I., Vague P., Selam J.L., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 7 (2005) 73-82
27. Standl E., Lang H., and Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 6 (2004) 579-588
28. Vague P., Selam J.L., Skeie S., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26 (2003) 590-596
29. Home P., Bartley P., Russell-Jones D., et al., Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care 27 (2004) 1081-1087
30. Haak T., Tiengo A., Draeger E., et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 7 (2005) 56-64
31. Murata G.H., Duckworth W.C., Shah J.H., et al. Hypoglycemia in stable, insulin-treated veterans with type 2 diabetes: A prospective study of 1662 episodes. J Diabetes Complications 19 (2005) 10-17
32. Cox D.J., Irvine A., Gonder-Frederick L., et al. Fear of hypoglycemia: Quantification, validation, and utilization. Diabetes Care 10 (1987) 617-621
33. Smith W.D., Winterstein A.G., Johns T., et al. Causes of hyperglycemia and hypoglycemia in adult inpatients. Am J Health Syst Pharm 62 (2005) 714-719
34. Schiel R., Ulbrich S., and Muller U.A. Quality of diabetes care, diabetes knowledge and risk of severe hypoglycaemia one and four years after participation in a 5-day structured treatment and teaching programme for intensified insulin therapy. Diabetes Metab 24 (1998) 509-514
35. Berlin I., Sachon C.I., and Grimaldi A. Identification of factors associated with impaired hypoglycaemia awareness in patients with type 1 and type 2 diabetes mellitus. Diabetes Metab 31 (2005) 246-251
36. Lepore M., Pampanelli S., Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
37. Riddle M.C., Rosenstock J., Gerich J., and Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
38. Ryan E.A., Lakey J.R., Rajotte R.V., et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50 (2001) 710-719
39. Johnson J.A., Kotovych M., Ryan E.A., and Shapiro A.M. Reduced fear of hypoglycemia in successful islet transplantation. Diabetes Care 27 (2004) 624-625
40. Available at:. Juvenile Diabetes Research Foundation. The history of diabetes & the search for a cure. Accessed (October 17, 2005). http://www.jdrf.org/au/publications/factsheets/historycure.html
41. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497